Pentixapharm Holding AG (FRA:PTP) 1-Year ROIIC % : -43.95% (As of Mar. 2026)


FRA:PTP Pentixapharm Holding AG FRA:PTP
20 GF Score
Price €2.20
! 2 Warning Signs
View Full Analysis

What is Pentixapharm Holding AG 1-Year ROIIC %?

Pentixapharm Holding AG FRA:PTP -4.35% 20 1-Year ROIIC % is -43.95 as of Mar. 2026. GuruFocus rates FRA:PTP with a GF Score™ of 20/100. The stock has 2 warning signs investors should review. Among 1,348 Biotechnology companies, Pentixapharm Holding AG ranks worse than 61.13% on this metric.

1-Year Return on Invested Incremental Capital (1-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 1-year. Pentixapharm Holding AG's 1-Year ROIIC % for the quarter that ended in Mar. 2026 was -43.95%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

The industry rank for Pentixapharm Holding AG's 1-Year ROIIC % or its related term are showing as below:

FRA:PTP's 1-Year ROIIC % is ranked worse than
61.13% of 1348 companies
in the Biotechnology industry
Industry Median: -9.345 vs FRA:PTP: -43.95

Pentixapharm Holding AG  (FRA:PTP) 1-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.


Pentixapharm Holding AG 1-Year ROIIC % Related Terms


Pentixapharm Holding AG 1-Year ROIIC % Historical Data

* Premium members only.

The historical data trend for Pentixapharm Holding AG's 1-Year ROIIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pentixapharm Holding AG 1-Year ROIIC % Chart

Pentixapharm Holding AG Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
1-Year ROIIC %
0.00 -2.06 -44.75 38.49 56.52

Pentixapharm Holding AG Quarterly Data
Dec21 Dec22 Dec23 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
1-Year ROIIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.00 98.90 0.00 56.52 -43.95

FRA:PTP vs VRTX, REGN, ALNY: 1-Year ROIIC % Comparison

For the Biotechnology subindustry, Pentixapharm Holding AG's 1-Year ROIIC %, along with its competitors' market caps and 1-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pentixapharm Holding AG 1-Year ROIIC % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pentixapharm Holding AG's 1-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where Pentixapharm Holding AG's 1-Year ROIIC % falls into.


FRA:PTP
20GF Score
Pentixapharm Holding AG FRA:PTP
1-Year ROIIC % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pentixapharm Holding AG 1-Year ROIIC % Calculation

Pentixapharm Holding AG's 1-Year ROIIC % for the quarter that ended in Mar. 2026 is calculated as:

1-Year ROIIC %=1-Year Incremental Net Operating Profit After Taxes (NOPAT)**/1-Year Incremental Invested Capital
=( -15.651 (Mar. 2026) - -17.7775 (Mar. 2025) )/( 35.924 (Mar. 2026) - 40.762 (Mar. 2025) )
=2.1265/-4.838
=-43.95%***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of NOPAT and Invested Capital was used to calculate 1-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.

Frequently Asked Questions Learn more about 1-Year ROIIC % →
What does a 1-Year ROIIC % of -43.95 mean?
Pentixapharm Holding AG (FRA:PTP) has a 1-Year ROIIC % of -43.95 as of Mar. 2026. 1-Year ROIIC % measures the change in earnings as a percentage of change in investment over 1-year. View historical data on Pentixapharm Holding AG and its competitors. According to the industry distribution chart, Pentixapharm Holding AG ranks #824 out of 1348 companies in the Biotechnology industry, placing it in the top 61.1%.
Is Pentixapharm Holding AG's 1-Year ROIIC % too high?
Pentixapharm Holding AG's current 1-Year ROIIC % is -43.95. Based on the distribution chart, Pentixapharm Holding AG ranks #824 out of 1348 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Pentixapharm Holding AG has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Pentixapharm Holding AG's 1-Year ROIIC % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Pentixapharm Holding AG ranks #824 out of 1348 companies for 1-Year ROIIC %. This places Pentixapharm Holding AG in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year ROIIC % for a Biotechnology company?
A good 1-Year ROIIC % depends on the Biotechnology industry context. However, 1-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year ROIIC % mean?
A high 1-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 1-Year ROIIC % measures the change in earnings as a percentage of change in investment over 1-year. View historical data on Pentixapharm Holding AG and its competitors. Pentixapharm Holding AG's current 1-Year ROIIC % is -43.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pentixapharm Holding AG stock overvalued right now?
Pentixapharm Holding AG (FRA:PTP) has a current 1-Year ROIIC % of -43.95. The current 1-Year ROIIC % is -43.95. Pentixapharm Holding AG's overall GF Score™ is 20/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year ROIIC % calculated?
1-Year ROIIC % is calculated from a company's financial statements. For Pentixapharm Holding AG (FRA:PTP), the current 1-Year ROIIC % is -43.95 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Pentixapharm Holding AG Business Description

Other Exchanges PTP:GermanyPTPN:Austria
Address Robert-Rossle-Street 10, Berlin, DEU, 13125
Pentixapharm Holding AG is a clinical-stage biopharmaceutical company active in the field of research and development of radiopharmaceuticals for diagnostic and therapeutic applications. Radiopharmaceuticals are medical substances containing radioactive elements used in nuclear medicine to diagnose or treat diseases. Its clinical pipeline encompasses PentixaTher, a Yttrium-90 based therapeutic against non-Hodgkin lymphomas (NHL), and PentixaFor, a Gallium-68-based companion diagnostic. Its Pipeline products include: Pentixa Ther, PT-002, PentixaFor, PT-001, PentixaFor, PT-001, PT-00X, GT-001, GT-002, GT-005, GT-008, and GT-00X.
20GF Score

Get the complete analysis for FRA:PTP

1-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.20
Price